Tolerability and effectiveness of preservativefree dorzolamide-timolol (preservative-free COSOPT®) in patients with open-angle glaucoma or ocular hypertension

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 581-590

  Hutnik, Cindy ^a   Neima, David ^b   Ibrahim, Fahim ^b   Scott, Robert ^b   Vaillancourt, Julie ^c   Haine, Denis ^c   Sampalis, John S ^c   Bastien, Natacha ^d   Foucart, Sylvain ^d  

^a Ivey Eye Institute   (Canada)

^b JSS Medical Research ^*

^c JSS Medical Research   (Canada)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Dorzolamide timolol; GSS SYMP 6; Intraocular pressure; Ocular hypertension; Open angle glaucoma; Preservative free

Indexed keywords

DORZOLAMIDE PLUS TIMOLOL;

ADULT; ARTICLE; BRADYCARDIA; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLAUCOMA SYMPTOM SCALE 6; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 77956129527     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/opth.s10337     Document Type: Article

References (37)

1. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109(8):1090-1095.
2. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull WHO. 2004;82(11):844-852.
3. Adatia FA, Damji KF. Chronic open-angle glaucoma. Review for primary care physicians. Can Fam Physician. 2005;51:1229-1237.
4. Lee AG, Beaver HA. Visual loss in the elderly-Part I: Chronic visual loss: what to recognize and when to refer. Clin Geriatr. 2003;11(6):46-53.
5. Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging. 2005;22(4):315-321.
6. Damji KF, Behki R, Wang L. Canadian perspectives in glaucoma management: setting target intraocular pressure range. Target IOP workshop participants. Can J Ophthalmol. 2003;38(3):189-197.
7. Frampton JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drug Aging. 2006;23(12):977-995.
8. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945-1951.
9. Choudhri S, Wand M, Shields MB. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am J Ophthalmol. 2000;130(6):832-833.
10. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105(10):1952-1959.
11. Fechtner RD, Airaksinen PJ, Getson AJ, et al. Efficacy and tolerability of the dorzolamide 2% timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand. 2004;82(1):42-48.
12. Fechtner RD, McCarroll KA, Lines CR, Adamsons IA. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies. J Ocul Pharmacol Ther. 2005;21(3):242-249.
13. Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS. Comparing the fixed combination dorzolamide-timolol (COSOPT) to concomitant administration of 2% dorzolamide (trusopt) and 0.5% timolol-a randomized controlled trial and a replacement study. COSOPT Study Group. J Clin Pharm Ther. 2004;29(4):375-380.
14. Gandolfi SA, Rossetti L, Cimino L, Mora P, Tardini M, Orzalesi N. Replacing maximum-tolerated medications with latanoprost versus adding latanoprost to maximum-tolerated medications: a two-center randomized prospective trial. J Glaucoma. 2003;12(4):347-353.
15. Henderer JD, Wilson RP, Moster MR, et al. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mmHg. J Glaucoma. 2005;14(4):267-270.
16. Hutzelmann J, Owens S, Shedden A, Adamson I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide/ timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82(11):1249-1253.
17. Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology. 2008;115(1): 99-103.
18. Rolle T, Tofani F, Brogliatti B, Grignolo FM. The effects of dorzolamide 2% and dorzolamide/timolol fixed combination on retinal and optic nerve head blood flow in primary open-angle glaucoma patients. Eye. 2008;22(9):1172-1179.
19. Whitson JT, Henry C, Hughes B, Lee DA, Terry S, Fechtner RD. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma. 2004;13(2):168-173.
20. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423.
21. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservativefree glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-349.
22. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients J Glaucoma. 2008;17(5):350-355.
23. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome Arch Ophthalmol. 2000;118(9):1264-1268.
24. Lee BL, Gutierrez P, Gordon M, et al. The glaucoma symptom scale. A brief index of glaucoma-specific symptoms. Arch Ophthalmol. 1998;116(7):861-866.
25. Canadian Ophthalmological Society. Evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44 Suppl 1:S7-S93.
26. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86(7):716-726.
27. Chawla A, McGalliard JN, Batterbury M. Use of eyedrops in glaucoma: how can we help to reduce non-compliance? Acta Ophthalmol Scand. 2007;85(4):464.
28. Beckers HJ, Schouten JS, Webers CA, van der Valk R, Hendrikse F. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1485-1490.
29. American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2005. Available from: http://one.aao.org/CE/PracticeGuidelines/PPPContent.aspx?cid=a5a59e02-450b-4d50-8091-b2dd21ef1ff2 (Accessed October 07, 2009).
30. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 2nd ed. Savona, Italy: The Society; 2003. Available from: http://www.eugs.org (accessed October 07, 2009)
31. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268-1279.
32. Martinez A, Sánchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study. Clin Ther. 2008; 30(6):1120-1134.
33. Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115(7):1117-1122.
34. Webers CA, van der Valk R, Schouten JS, Zeegers MP, Prins MH, Hendrikse F. Intraocular pressure-lowering effect of adding dorzolamide or latanoprost to timolol: a meta-analysis of randomized clinical trials. Ophthalmology. 2007;114(1):40-46.
35. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 2001;22(1):8-18.
36. Liesegang TJ. Conjunctival changes associated with glaucoma therapy: implications for the external disease consultant and the treatment of glaucoma. Cornea. 1998;17(6):574-583.
37. Pasquale LR, Kang JH. Lifestyle, nutrition, and glaucoma. J Glaucoma. 2009;18(6):423-428.